1. Home
  2. NEPH vs BTAI Comparison

NEPH vs BTAI Comparison

Compare NEPH & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nephros Inc.

NEPH

Nephros Inc.

N/A

Current Price

$3.95

Market Cap

45.3M

Sector

Health Care

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

N/A

Current Price

$1.76

Market Cap

35.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEPH
BTAI
Founded
1997
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.3M
35.6M
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
NEPH
BTAI
Price
$3.95
$1.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$6.00
$25.33
AVG Volume (30 Days)
41.5K
952.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
106.67
N/A
EPS
0.10
N/A
Revenue
$14,162,000.00
N/A
Revenue This Year
$33.32
N/A
Revenue Next Year
$12.27
$261.81
P/E Ratio
$38.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.49
$1.17
52 Week High
$6.42
$8.08

Technical Indicators

Market Signals
Indicator
NEPH
BTAI
Relative Strength Index (RSI) 48.28 56.40
Support Level $3.48 $1.50
Resistance Level $4.27 $2.13
Average True Range (ATR) 0.30 0.13
MACD 0.03 0.01
Stochastic Oscillator 61.09 83.25

Price Performance

Historical Comparison
NEPH
BTAI

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: